Human leukocyte antigen (HLA)-C is a clinically relevant transplantation antigen in unrelated hematopoietic stem cell and cord blood transplantation. Furthermore, HLA-C antigens, as ligands for killer immunoglobulin-like receptors expressed on natural killer cells, have a central role in HIV control. Several studies have reported significant correlations between HLA-C mRNA and cell surface expression with polymorphisms in the 5 0 -and 3 0 -regions of the HLA-C locus. We determined HLA-C mRNA in blood donors by using locus as well as allele-specific real-time-PCR and focused the analysis on HLA-extended haplotypes. High inter-individual variability of mRNA expression was disclosed. A lower inter-individual variability for C*07:01 but a higher variability for C*06:02, C*04:01 and C*03:04 alleles were detected. The previously reported associations between HLA-C cell surface expression and À 32 kb/ À 35 kb single nucleotide polymorphisms were not confirmed. Related and unrelated individuals sharing the same two A-B-C-DRB1 or B-C haplotypes show strikingly similar levels of HLA-C mRNA expression in each of the different haplotypic combinations tested. Altogether, our results suggest that HLA-C expression levels best correlate with the extended HLA haplotype rather than with the allotype or with polymorphisms in the 5 0 -region of the HLA-C locus.
INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) is a recognized treatment for a number of hematological malignancies and disorders of the immune system. In the western countries, hematopoietic stem cells (HSCs) from highly matched unrelated donors are increasingly used. 1 Matching criteria in most transplant centers include allelic compatibility for the human leukocyte antigen (HLA)-A,B,C,DRB1,DQB1 loci, a so-called 10/10 match. 2, 3 In the absence of a compatible donor for HSCT, a donor with a single allele mismatch is often the best option. Among such 9/10 matched donors, HLA-C incompatibilities account for a large fraction of the HLA class I/II disparities, [4] [5] [6] [7] and their clinical relevance has been documented in several studies. 2, 3, [6] [7] [8] [9] The impact of HLA-C disparities on T-cell alloreactivity could be influenced by the expression level of HLA-C antigens at the cell surface. Low-expression HLA-C alleles could thus possibly represent good candidates for more permissive mismatches. HLA-C surface expression is controlled at the transcriptional, translational and post-translational levels. HLA-C mRNA has a higher turn-over rate which could account for the lower HLA-C cell surface expression compared with HLA-A or -B antigens. 10 In addition, owing to a selective preference in the peptide repertoire, HLA-C heavy chains associate with b2-microglobulin less efficiently than HLA-A and -B antigens. [11] [12] [13] [14] A first genome-wide association study screening of HIV-infected patients led to the discovery of a single nucleotide polymorphism (SNP) 35 kb upstream of the HLA-C transcription start site ( À 35C/T) that was associated with the viral load set point. The À 35C allele correlated with lower viral set point, 15 higher CD4 þ -T-cell counts and HLA-C mRNA levels in individuals of European ancestry. 16, 17 Thomas et al. 18 reported that HLA-C alleles in linkage disequilibrium with the À 35C SNP had a higher cell surface expression, as determined by DT9 antibody staining. However, Corrah et al. 19 reported that the differences in expression levels could be accounted by the low expression of HLA-Cw7 antigen only, which is strongly linked to À 35T. HLA-C*07/*07-and À 35TT-positive individuals showed a fivefold lower cell surface expression of HLA-C compared with C*07-negative À 35CC individuals. The protective À 35C genotype does not associate with higher HLA-C expression they argued, but rather the nonprotective À 35T allele was associated with the much lower expression of a single allele, C*07. 19 Further insight in the regulation of HLA-C expression was provided by Kulkarni et al. 20 who showed that a polymorphism in the 3 0 -untranslated region (UTR) controls the binding of micro-RNA (miR)-148, with lower expression of HLA-C alleles that bind miR-148 and higher expression of C alleles that do not bind miR-148. Interestingly, this miR-148 binding site was present in the common ancestor of all the extant HLA-C alleles. 21 A correlation of the À 35-kb SNP and the 3 0 -UTR polymorphism and HLA-C surface expression as determined by DT9 binding has also been reported on a small cohort of healthy blood donors. 22 A higher HLA-C expression might allow a greater recognition by the KIR2DL receptors during natural killer (NK) cell maturation, leading to more effective natural killer responses against infected cells, 18 although HLA-C expression was recently reported to have no effect on natural killer cell function in healthy individuals. 22 Higher HLA-C expression is also expected to allow a more efficient presentation of viral peptides to cytotoxic T lymphocytes. 23 Haplotype-specific variations in transcripts as determined by microarray hybridization have been reported for a number of major histocompatibility complex genes, including the classical HLA class I or II loci, upon analysis of the transcriptome of three HLA homozygous cell lines COX, QBL and PGF. 24 Haplotypespecific differences in gene expression was reported for 96 genes across the major histocompatibility complex. In particular, HLA-C expression was higher in QBL (C*05:01) compared with COX (C*07:01) and PFG (C*07:02). Alternative splicing was also haplotype-dependant and 526 exons showed haplotypic differences, including HLA-DPB2, DQB2, HLA-C or HLA-G. 24 An analysis of HLA-C mRNA expression in skin samples from healthy donors and psoriatic patients revealed a large heterogeneity in both C*06:02-positive and C*06:02-negative patients. 25 As a C/T dimorphism at À 35 kb of HLA-C locus has been reported to be predictive of HLA-C expression, 18 we aimed to reproduce this result in order to use this SNP as a surrogate marker for HLA-C expression in the HSCT setting. We furthermore tested the hypothesis that HLA-C expression could be, at least partially, regulated in a HLA haplotype-dependant manner. We report here a large heterogeneity in HLA-C allotypes mRNA expression, and show correlations with HLA-A-B-DRB1 haplotypes but not with the À 35C/T dimorphism.
RESULTS
Correlation with À 35 kb/ À 32 kb SNPs HLA-C mRNA levels were quantified by reverse transciptase (RT)-PCR in 130 donors using locus-specific primers. Of these 130 donors, 107 were typed in parallel for the two SNPs at À 35 kb and À 32 kb, respectively. As shown in (Figure 1 ), HLA-C mRNA analysis did not reveal any significant association between the expression levels and the -35CC, CT and TT genotypes. Furthermore, when analyzing the C*07-35TT homozygous donors separately, neither any difference was disclosed nor any correlation was revealed with the À 32-kb genotypes (data not shown).
Total HLA-C mRNA expression HLA-C mRNA levels, as determined by locus-specific RT-PCR, are represented in Figure 2 for each allotype in 130 HLA-C allele-typed individuals. This study group (heterozygosity rate ¼ 87.7%) showed, as expected, a large representation of the most frequent alleles C*04:01, C*05:01, C*06:02, C*07:01 and C*07:02. In the whole study group, a large variability in mRNA levels was disclosed.
HLA-C*04:01 (n ¼ 4) and C*07:02 (n ¼ 5) homozygous blood donors (open circles in Figure 2 ) showed a homogenous distribution. Considering a mean HLA-C expression value of 11.5 (horizontal dotted line in Figure 2 ), several alleles such as C*01:02, C*02:02, C*03:03, C*07:02 or C*16:01 found in heterozygous individuals were associated with a lower expression, whereas other alleles such as C*03:04, C*07:04 or C*15:02 were linked to a higher mean expression level. For example, as compared with the C*03:04-positive individuals, mean expression levels were significantly (Mann-Whitney test) lower for C*01:02-(P ¼ 0.05), C*02:02-(P ¼ 0.04), C*07:02-(P ¼ 0.02) and C*16:01-positive individuals (P ¼ 0.02).
Interestingly, three samples from the same family with the B*49:01-C*07:01 haplotype and three different C allotypes on the second haplotype (C*03:04, C*04:01 and C*15:02) showed a strikingly high HLA-C mRNA expression level with a mean expression value of 15.4. As these belonged to the same family and originated from nonEuropean ancestry they were not included in Figure 2 .
Because of the coamplification of two different alleles in heterozygous samples, we sought to investigate the impact of the second allele. We therefore grouped the C*07:01- ( compared with the expression patterns detected with the coamplification of the two C alleles (referred to as total HLA-C expression). Interestingly, 22/27 HLA-C*07:01-positive individuals had the B*08:01 allele and 18/27 had the A1-B8-DR3 or A1-B8 or B8-DR3 haplotype. In contrast, the C*06:02-, C*04:01-and C*03:04-specific mRNA expression were more heterogenous (Figures 4b-d , respectively). Pairwise comparisons between total and specific expression, as represented in lower panels of Figure 4 , showed poor correlation coefficients (R 2 ¼ 0.3 for C*07:01, R 2 ¼ 0.6 for C*06:02, R 2 ¼ 0.8 for C*04:01 and R 2 ¼ 0.4 for C*03:04), indicating that total HLA-C mRNA is the sum of two alleles with possibly very different expression levels. Extreme examples are found in Figure 4d where the individual (C*03:04/16:01) with the lowest total HLA-C mRNA expression has a moderate C*03:04 expression (haplotype B*40:01-C*03:04) and the individual (C*03:04/04:01) with the highest total HLA-C mRNA expression has a very low C*03:04 expression (haplotype B*15:01-C*03:04), whereas for other samples, high HLA-C total mRNA expression was linked to high expression of both alleles.
Haplotype-linked HLA-C mRNA expression Despite the high HLA-A,B,DRB1 haplotypic diversity of the individuals tested, we investigated possible correlation of HLA-C*04:01-specific mRNA expression with different haplotypes. Interestingly, among the group of 26 C*04:01 heterozygous individuals with normalized expression varying from 8.00-10.97 (Figure 4c ), a few haplotypes exhibited more homogenous C*04:01 mRNA expression levels. For example, four A*11:01-B*35:01-C*04:01 haplotypes associated with nonDRB1*11:01 alleles were expressed at a relatively high level (10.36-10.65 ) and three A*03:01-B*35:01-C*04:01-DRB1*01:01 haplotypes had also a narrow range of expression (9.36-10.28). Two HLA-C*04:01 homozygous donors with the A*01:01-B*35:02-C*04:01-DRB1*13:02/A*01:01-B*35:01-C*04:01-DRB1*01:01 haplotypes expressed very similar C*04:01 mRNA levels (8.83-9.41) (data not shown).
As variation within individuals sharing the very same HLA-C genotypes, and variations of allele-specific expression levels were observed, we hypothesized that HLA-C mRNA expression could be at least partly associated with the HLA haplotypes. As shown in 
DISCUSSION
The crucial role of HLA-C molecules as ligands of killer immunoglobulin-like receptors on natural killer cells has led to a growing interest in investigating the expression of HLA-C antigens both at the mRNA and protein levels in relationship with HIV infection. 15, 18, 23 On the basis of the hypothesis that in mismatched allogeneic HSCT, T-cell alloreactivity could be modulated by differential expression of HLA-C target antigens, we analyzed HLA-C mRNA levels in a large cohort of patients and HSC donors. We choose to use RT-PCR for the determination of HLA-C expression rather than cell surface expression as quantified by the DT9 antibody. One reason resided in the debated issue on the crossreactivity of the DT9 antibody with HLA-E, 18, 19 but the main argument was that the allele-specific PCR allowed us to test and compare the expression of single HLA-C alleles in a large sample of donors. First, we report that the analysis of mRNA expression with generic primers allowed robust, reproducible and precise inter-individual comparisons, although its limitation resides in the lack of discrimination of individual HLA-C alleles except in homozygotes. The purpose of this study was to disclose possible relationship between expression levels and polymorphisms in the 5 0 -region of HLA-C locus and HLA-extended haplotypes. Although most tested individuals are heterozygous and high inter-individual variability is observed, certain allotypes showed higher mean expression levels ( Figure 2 ). Particularly striking are the C*15:02-positive individuals that are associated with a higher mean expression compared with C*01:02-(P ¼ 0.01), C*02:02-(P ¼ 0.004) C*04:01-(P ¼ 0.03), C*07:01-(P ¼ 0.03), C*07:02-(P ¼ 0.003) and C*16:01-positive (P ¼ 0.007) donors. Similar to previous studies 18, 19 we find a lower, but not significant, mean expression level for C*07:02-positive individuals. Strikingly, C*07:04-positive individuals exhibited a high mean expression level with all donors sharing the B*44:02 haplotype.
As a new finding reported in this study, the large heterogenity in HLA-C mRNA expression correlated best with HLA-B-C haplotypes. Several arguments support a HLA-B-C haplotypespecific expression of HLA-C antigens rather than a control by À 35 kb/ À 32 kb SNPs. First, although a large heterogeneity of HLA-C mRNA expression was detected for most HLA-C allotypes (Figure 2 ), the expression was homogenous in HLA-B, -C homozygous individuals (for example B*35-C*04:01 and B*07-C*07:02 donors, legend to Figure 2) . Second, 81% of HLA-C*07:01-positive individuals showing more homogenous allele-specific expression have B*08:01-positive haplotypes (Figure 4) . Third, the analysis of 11 groups of heterozygous individuals (7 unrelated and 4 related) with the same two HLA-A-B-C-DRB1 or HLA-B-C haplotypes ( Figure 5 ) revealed a rather narrow variation in the HLA-C mRNA expression levels.
Two studies have reported gradients of HLA-C expression on peripheral blood lymphocytes as determined by DT9 antibody binding in European-American 18 and in African-American individuals. 23 A correlation with the À 35-kb SNP was reported in the first study. 18 Subsequently, Kulkarni et al. 20 showed that variation in the 3 0 -UTR-263 miR-148 binding site correlated best with HLA-C expression on the basis of in vitro studies using HLA-C transfectants. However, by comparing HLA-C expression levels as determined by DT9 binding 18, 23 with the 3 0 -UTR-263 indel polymorphism defining HLA-C expression, 20 somewhat opposite conclusions are observed. For example, the two alleles classified with the highest average DT9 binding (C*01:02, C*14:02) 23 are characterized by an intact miR-148 binding site resulting in HLA-C downregulation. 20 Similarly, C*04:01 lies among the C alleles with a high cell surface expression, but nevertheless is associated with the 263ins genotype linked to low expression. These apparently divergent results suggest that the control of HLA-C expression might be more complex than expected. Interestingly, a most recent study showed that differential expression levels of miR-148a, as determined by a polymorphism at the MIR-148A locus changed the HLA-C expression levels, but only in individuals homozygous for the ins263 intact binding site. 26 The presence of an additional putative miR181a binding site in the 3 0 -UTR 26, 27 adds to further diversity and may also contribute to HLA-C expression variability. It is furthermore interesting to note that the C*02:10 allele, frequent in some African populations, was found to be associated with both the 3 0 -UTR 263ins (low-expression) and 263del (high-expression) alleles. 27 Altogether, the lack of correlation between the À 35-kb SNP and HLA-C expression reported here and in previous studies in both Caucasoid and African population groups 27, 28 show that À 35 kb genotyping cannot be used as a marker for HLA-C expression. Although we confirm the lower expression of C*07:02 alleles observed by others, 19, 23 it is not easy to compare mean HLA-C expression levels reported in different populations with presumably completely different HLA haplotypes. We consider that the differences observed for some HLA-C allotypes in this and previous studies 18, 23 can be accounted for by the different haplotypic associations in the study groups.
Our results on the basis of allele-specific RT-PCR show that a given allele might not be simply classified as a high-or lowexpression allele, and that the HLA-A-B-DRB1 haplotypic association could significantly impact on the level of expression in addition to the miR-148a regulatory pathway. 20, 26 As determined in lymphoblastoid cell lines, transcription maps of three common major histocompatibility complex haplotypes have shown significant variations in the transcriptional activity of 46.4% genes in the major histocompatibility complex including HLA-C. HLA-B and HLA-C genes are 88 kb apart and transcribed in the same orientation. Considering the haplotype-specific transcriptionally active regions described in lymphoblastoid cell lines, 24 it is possible that long-range regulatory elements may affect transcription of the whole subregion. Haplotype-linked variation in HLA-C expression is expected to impact on allorecognition of specific target HLA-C antigen mismatches in transplantation. Although expressed at a lower level compared with HLA-A or -B antigens, incompatible HLA-C molecules can be efficiently recognized by alloreactive T lymphocytes as shown in HSCT. [29] [30] [31] Cytotoxic T-lymphocyte precursor frequency assays have disclosed several HLA-C-mismatched combinations which did not induce a positive test. 32 It could be expected that in cytotoxic T-lymphocyte precursor frequency-negative pairs, target HLA-C antigens are encoded by a haplotype with a lower transcriptional activity. On the other hand, HSC donors with a lower self-HLA-C expression in the thymus could become high responders toward incompatible HLA-C antigens because of a more limited negative selection of T cells.
In disease association studies, the importance of HLA-C expression in modulating the immune response has been demonstrated by the highly significant correlation between high HLA-C expression and a more efficient control of HIV infection, 18, 23 but a higher risk of Crohn's disease (CD). 23 A direct effect of HLA-C expression level on HIV control and on CD was recently shown to be mediated by a MIR-148A polymorphism. 26 We consider the possibility that the highly expressed HLA-C alleles conferring a higher risk of CD 23, 26 are found on different haplotypes compared with healthy individuals. Interestingly, a genome-wide association study analysis of a Japanese population disclosed a B-C-DRB1 haplotype that correlated with decreased susceptibility to CD 33 In several autoimmune diseases HLA class II loci (mainly DRB1) stand out as the major genetic risk determinants, 34 but class I and II alleles seem to contribute to susceptibility, such as HLA-C*08 in CD, and HLA-C*05 in type I diabetes and rheumatoid arthritis. 35 It is tempting to suggest that the previously reported associations of HLA-A and -B alleles with type I diabetes 36 could be accounted for by the strong linkage with HLA-C alleles that has an impact on either innate and/or on adaptive anti-islet b-cell class I-mediated responses. Large scale disease association studies should therefore include entire HLA haplotype analyses and undoubtedly next generation sequencing will contribute to such a goal.
SUBJECTS AND METHODS

HLA and SNP genotyping
The SNPs À 32 kb (rs6457374) and À 35 kb (rs924942) were typed using a TaqMan SNP genotyping assay and allelic discrimination on a real time-PCR System 7300 (Applied Biosystems, Life Technologies, Foster City, CA, USA). 
HLA-C mRNA quantification
Total RNA was extracted from peripheral blood of 130 donors (26 patients, 101 potential HSC donors and 3 volunteers), using the RNeasy Micro kit (Qiagen, Valencia, CA, USA) and according to manufacturer's instructions. RNA was reverse transcribed with the M-MLV H-Minus (Promega, Madison, WI, USA) reverse transcriptase and random oligo dT 15mer-primers in presence of rRNAsin (Promega). cDNA was quantified relative to 18S RNA using SYBR Green/Rox (Abgene, Epsom, UK) based quantitative real time-PCR on a real time-PCR System 7300 using SDS software version 1.3.10.2 (Applied Biosystems). In a set of preliminary experiments, the SYBR Green assay has been compared with the TaqMan assay (HLA-C: Hs00762610_sl/ 18S: Hs99999901_sl) (Applied Biosystems) and shown to be more sensitive (Supplementary Figure S1) . The results were expressed as 100/DCt (Ct HLA-C À Ct 18S). A 100/DCt of 1.5 corresponds to 100% expression increase.
The primers used for total HLA-C expression were located in exons 5 and 7, respectively: forward primer 5 0 -ATCGTTGCTGGCCTGGCTGTCCT-3 0 and reverse primer 5 0 -TCATCAGAGCCCTGGGCACTGTT-3 0 . 18 For the 18S amplification the forward and reverse primers 5 0 -GTAACCCGTTGA ACCCCATT-3 0 and 5 0 -CCATCCAATCGGTAGTAGCG-3 0 were used. HLA-C allele-specific primers have been previously described. 37 The following forward/reverse primers were used: 5 0 -GGACCGGGAGACACAGAAC-3 0 , 5 0 -CGCACGGGCCGCCTCCA-3 0 for HLA-C*07:01, 5 0 -CACAGACTGACCGAGTGAG-3 0 , 5 0 -CCGCCGTGTCCGCGGCA-3 0 for HLA-C*06:02, 5 0 -CCGAGTGAACCTGCGGAAA-3 0 , 5 0 -CCCCAGGTCGCAGCCAA-3 0 HLA-C*04:01, and 5 0 -CACAGACTGACCGAGTGAG-3 0 , 5 0 -AGCGTCTCCTTCC-CATTCTT-3 0 for HLA-C*03:04. 37 The specificity of the amplifications was controlled by amplification of allele-positive and -negative cDNAs and sequence analysis of the respective amplicons. For each primer pair cDNA dilutions curves showed the same slope (Supplementary Figure S2) , indicating that allele-specific and locus-specific HLA-C amplification are comparable. Furthermore, control experiments where HLA-C expression of different blood samples of the same donor taken at different time points and kept in sodium citrate up to 7 days allowed us to monitor reproducibility and storage time of blood samples. cDNAs obtained from peripheral blood lymphocytes isolated from blood samples kept up to 3 days gave the same results and were thus included in the study (Supplementary Figure S3) . As a further control, repeated total HLA-C amplifications of the same cDNA samples at different experimental dates (n ¼ 3 for 5 cDNAs) revealed a low 0.4 100/DCt s.d. One blood sample taken from a healthy volunteer donor at one-year interval showed similar 100/DCt values: 12.42 in 2012, 13.07 in 2013.
